| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 01/24/2013 | US20130023498 MicroRNA Modulators and Method for Identifying and Using the Same |
| 01/24/2013 | US20130023497 Triazine Derivatives and their Therapeutical Applications |
| 01/24/2013 | US20130023496 Combination Therapy Comprising A CCR5 Antagonist, A HIV-1 Protease Inhibtior and a Pharmacokinetic Enhancer |
| 01/24/2013 | US20130023495 Uses of dgat1 inhibitors |
| 01/24/2013 | US20130023494 Modulators of the gpr119 receptor and the treatment of disorders related thereto |
| 01/24/2013 | US20130023493 Andrographis paniculata extract |
| 01/24/2013 | US20130023492 Pharmaceutical compositions comprising plant-based polysaccharides and uses thereof |
| 01/24/2013 | US20130023491 Beta-cell replication promoting compounds and methods of their use |
| 01/24/2013 | US20130023490 Topical formulations comprising 1-n-arylpyrazole derivatives and amitraz |
| 01/24/2013 | US20130023489 Compositions and methods for preventing and treating diseases and environmentally induced health disorders |
| 01/24/2013 | US20130023488 Methods and compounds for reducing intracellular lipid storage |
| 01/24/2013 | US20130023487 Compounds and compositions for treating infection |
| 01/24/2013 | US20130023486 Phenyl c-glucoside derivatives, preparation methods and uses thereof |
| 01/24/2013 | US20130023473 Methods and pharmaceutical composition for the preservation of vascular endothelial cell barrier integrity |
| 01/24/2013 | US20130023472 Ldl quantitation and method of use |
| 01/24/2013 | US20130023463 Hiv protease inhibiting compounds |
| 01/24/2013 | US20130023461 Oligopeptide compounds and uses thereof |
| 01/24/2013 | US20130023411 Pesticidal Mixtures Comprising Cyanosulfoximine Compounds |
| 01/24/2013 | US20130022689 Use of Amisulpride as an Anti-Emetic |
| 01/24/2013 | US20130022688 Use of Amisulpride as an Anti-Emetic |
| 01/24/2013 | US20130022687 Topical transdermal method for delivering nutrients through the skin for expedited wound healing |
| 01/24/2013 | US20130022685 Topical Compositions and Methods of Detection and Treatment |
| 01/24/2013 | US20130022684 Oral pharmaceutical composition comprising fenofibric acid and an alkalifying agent |
| 01/24/2013 | US20130022683 Method for improving dissolution of anticoagulant agent |
| 01/24/2013 | US20130022682 Ultra-Stable Oligonucleotide-Gold And-Silver Nanoparticle Conjugates And Method Of Their Preparation |
| 01/24/2013 | US20130022681 Granules for pharmaceutical preparations, methods and apparatus for their production |
| 01/24/2013 | US20130022679 Controlled Release and Taste Masking Oral Pharmaceutical Composition |
| 01/24/2013 | US20130022678 Oral controlled release dosage form |
| 01/24/2013 | US20130022677 Delayed prolonged drug delivery |
| 01/24/2013 | US20130022676 Pulsatile drug release |
| 01/24/2013 | US20130022674 Pharmaceutical delivery systems for hydrophobic drugs and compositions comprising same |
| 01/24/2013 | US20130022673 Enhancement of magnesium uptake in mammals |
| 01/24/2013 | US20130022671 Controlled release compositions of agents that reduce circulating levels of platelets and methods therefor |
| 01/24/2013 | US20130022670 Aqueous Pharmaceutical Formulation of Tapentadol for Oral Administration |
| 01/24/2013 | US20130022668 Biologically Active Taxane Analogs And Methods Of Treatment By Oral Administration |
| 01/24/2013 | US20130022667 Fidgetin-like 2 as a target to enhance wound healing |
| 01/24/2013 | US20130022665 Cationic lipids for therapeutic agent delivery formulations |
| 01/24/2013 | US20130022662 Compressed chewing gum tablet comprising taste-masking agent |
| 01/24/2013 | US20130022661 Bio-remodable bone augmentation device and method |
| 01/24/2013 | US20130022660 Drug delivery system for the prevention of cerebral vasospasm |
| 01/24/2013 | US20130022654 Controlled release pharmaceutical compositions of tapentadol |
| 01/24/2013 | US20130022652 Stable medicated chewing gum comprising cyclodextrin inclusion complex |
| 01/24/2013 | US20130022651 Hydrogel materials incorporating eluting ceragenin compound |
| 01/24/2013 | US20130022650 Compositions containing salmeterol, fluticasone and cromoglicic acid |
| 01/24/2013 | US20130022649 Snalp formulations containing antioxidants |
| 01/24/2013 | US20130022647 Polymers for reversing heparin-based anticoagulation |
| 01/24/2013 | US20130022646 Controlled Release Formulations of Opioids |
| 01/24/2013 | US20130022645 Pharmaceutical formulations of bisphosphonate with enhanced oral bioavailability |
| 01/24/2013 | US20130022644 Novel n-phenylacetamide derivatives, which inhibit the enzyme soat-1, and pharmaceutical and cosmetic compositions containing them |
| 01/24/2013 | US20130022643 Antimicrobial Anti-chafing Chelated Silver Oxide Compound |
| 01/24/2013 | US20130022641 Anti-Tumor Agent and Immunostimulating Agent |
| 01/24/2013 | US20130022632 Recombinant feline leukemia virus vaccine containing optimized feline leukemia virus envelope gene |
| 01/24/2013 | US20130022629 Modulators of Immunoinhibitory Receptor PD-1, and Methods of Use Thereof |
| 01/24/2013 | US20130022624 Anti-epidermal growth factor receptor antibodies and uses thereof |
| 01/24/2013 | US20130022622 Compounds for the treatment of autism |
| 01/24/2013 | US20130022617 Compositions and methods for treating tumors, fibrosis, and pulmonary alveolar proteinosis |
| 01/24/2013 | US20130022611 Methods and compositions for modulating hepsin activation of urokinase-type plasminogen activator |
| 01/24/2013 | US20130022610 Methods of decreasing glycosylated hemoglobin in patients with dyslipidemia |
| 01/24/2013 | US20130022609 Method of treating androgen independent prostate cancer |
| 01/24/2013 | US20130022602 Methods and compositions to modulate antiviral and immune activity responses |
| 01/24/2013 | US20130022594 Selective fak inhibitors |
| 01/24/2013 | US20130022593 Methods of diagnosing endometriosis |
| 01/24/2013 | US20130022587 Cycloalkyl-Substituted Imidazole Derivative |
| 01/24/2013 | US20130022578 Methods and system for interfering with viability of bacteria and related compounds and compositions |
| 01/24/2013 | US20130022570 Crosslinked polyvinylamine, polyallylamine, and polyethyleneimine for use as bile acid sequestrants |
| 01/24/2013 | US20130022569 Hydrogels |
| 01/24/2013 | US20130022564 Compositions and methods for dermally treating infections |
| 01/24/2013 | US20130022553 Novel polyamino polyketide antibiotics and uses thereof |
| 01/24/2013 | US20130022552 Blood clotting composition and method of use |
| 01/24/2013 | US20130022545 DRUG DELIVERY SYSTEM FOR TREATMENT OF LIVER CANCER BASED ON INTERVENTIONAL INJECTION OF TEMPERATURE AND pH-SENSITIVE HYDROGEL |
| 01/24/2013 | US20130020226 Product for parenteral nutrition of obese intensive-care patients |
| 01/24/2013 | DE102011108227A1 Pharmazeutische Zusammensetzung zur Behandlung einer Atemwegserkrankung A pharmaceutical composition for the treatment of a respiratory disease |
| 01/24/2013 | DE102011108116A1 Reserpin zur Behandlung von kognitiven Störungen des zentralen Nervensystems Reserpine for the treatment of cognitive disorders of the central nervous system |
| 01/24/2013 | DE102011079540A1 Leistungsgesteigerte Wirkstoffkombination und Haarbehandlungsmittel gegen Schuppen I Increasing the Performance of drug combination and hair treatment remedy for dandruff I |
| 01/24/2013 | DE102011079539A1 Leistungsgesteigerte Wirkstoffkombination und Haarbehandlungsmittel gegen Schuppen II Increasing the Performance of drug combination and hair treatment remedy for dandruff II |
| 01/24/2013 | DE102011079538A1 Alkoholisches Haarbehandlungsmittel mit Poly-L-Lysin Alcoholic hair-treatment compositions with poly-L-lysine |
| 01/24/2013 | DE102011079537A1 Tensidsiches Haarbehandlungsmittel mit Poly-L-Lysin I Tensidsiches hair treatment compositions with poly-L-lysine I |
| 01/24/2013 | DE102011079536A1 Tensidsiches Haarbehandlungsmittel mit Poly-L-Lysin II Tensidsiches hair treatment compositions with poly-L-lysine II |
| 01/24/2013 | CA2877994A1 Targeted osmotic lysis of cancer cells |
| 01/24/2013 | CA2846517A1 Vaginal tissue rejuvenation compositions and methods |
| 01/24/2013 | CA2842682A1 Methods for determining patient response to anti-platelet aggregation therapy |
| 01/24/2013 | CA2842654A1 Process for the preparation of a pharmaceutical composition containing pirfenidone in sustained-release tablet form and its application in the regression of human chronic renal failure, breast capsular contracture and hepatic fibrosis |
| 01/24/2013 | CA2842550A1 Intravaginal devices for drug delivery |
| 01/24/2013 | CA2842505A1 Pyrazolo[3,4-d]pyrimidine compounds, their preparation and use as sigma ligands |
| 01/24/2013 | CA2842352A1 3-(fluorvinyl)pyrazoles and the use thereof |
| 01/24/2013 | CA2842316A1 Novel crystalline forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione |
| 01/24/2013 | CA2842277A1 Topical oily foam formulations |
| 01/24/2013 | CA2842273A1 Patch containing diclofenac and thiocolchicoside |
| 01/24/2013 | CA2842272A1 Fatty acid compositions |
| 01/24/2013 | CA2842228A1 Combination treatment for cancer |
| 01/24/2013 | CA2842195A1 Fty720 increases cd74 expression and sensitizes cancer cells to anti-cd74 antibody-mediated cell death |
| 01/24/2013 | CA2842190A1 Heterocyclic compounds and uses thereof |
| 01/24/2013 | CA2842187A1 Heterocyclic compounds and uses thereof |
| 01/24/2013 | CA2842175A1 Tablet containing dehydroepiandrosterone (dhea) |
| 01/24/2013 | CA2842034A1 Protection of cells from alu-rna-induced degenereation and inhibitors for protecting cells |
| 01/24/2013 | CA2842015A1 Imino-sugar c-glycosides, preparation and use thereof |
| 01/24/2013 | CA2841986A1 Use of coumarin derivatives for the preparation of drugs for treating skin diseases |
| 01/24/2013 | CA2841969A1 Fixed dose combination of bimatoprost and brimonidine |
| 01/24/2013 | CA2841964A1 Methods of treating pain |
| 01/24/2013 | CA2841960A1 Novel compositions and methods for treating prostate cancer |